Global /United States /Healthcare /Drug Manufacturers - General /RNXT

RenovoRx, Inc.

RNXT

• NASDAQ: RNXT • Delayed

0.8311USD -1.1%

As of 13 June 2026, RenovoRx, Inc. has a market cap of $37.44M USD, ranking #32651 globally and #4647 in the United States. It ranks #2946 in the Healthcare sector, and #1017 in the Drug Manufacturers - General industry.

Global Rank

32651

Country Rank

4647

Sector Rank

2946

Industry Rank

1017

Key Stats

Market Cap

$37.44MUSD

Enterprise Value

$31.03MUSD

Revenue (TTM)

$1.12MUSD

EBITDA (TTM)

-$12.01MUSD

Net Income (TTM)

-$11.17MUSD

PS Ratio

33.7

PB Ratio

5.7

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Shaun Bagai open_in_new

Employees

Founded

2012

IPO

26 Aug 2021

Website

renovorx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.1%	-13%	-27%	-8.6%	-27%	-2%	-15%	-74%	-90%

News

RNXT Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	RNXT RenovoRx Inc ISIN: US75989R1077 Shares Out.: Shares Outstanding: 45.053M¹ Shares Float: 43.48M² TV: TradingView: NASDAQ: RNXT SA: Stock Analysis: NASDAQ: RNXT YF: Yahoo Finance: RNXT GF: Google Finance: NASDAQ: RNXT NQ: NASDAQ: RNXT BA: Barron's: RNXT MS: Morningstar: XNAS: RNXT	0.8311 USD	TV: TradingView: NASDAQ: RNXT SA: Stock Analysis: NASDAQ: RNXT YF: Yahoo Finance: RNXT GF: Google Finance: NASDAQ: RNXT NQ: NASDAQ: RNXT BA: Barron's: RNXT MS: Morningstar: XNAS: RNXT

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About RenovoRx, Inc.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 2M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 1M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 963K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 732K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 399K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 314K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 859K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 771K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 733K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 485K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 294K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 290K%	14.6	United Kingdom

chevron_leftBack